NCT03478098

Brief Summary

The study will evaluate postprandial glucose excursions and gut hormone secretion after ingestion of meals with different glycaemic index (GI) values (high vs low) followed by an acute bout of exercise or rest in gastric bypass operated subjects and matched control subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 6, 2018

Completed
23 days until next milestone

Study Start

First participant enrolled

March 1, 2018

Completed
26 days until next milestone

First Posted

Study publicly available on registry

March 27, 2018

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

June 15, 2023

Status Verified

June 1, 2023

Enrollment Period

2 years

First QC Date

February 6, 2018

Last Update Submit

June 13, 2023

Conditions

Keywords

Gut hormonesGlucose excursions

Outcome Measures

Primary Outcomes (2)

  • Impact of acute bout of exercise on nadir plasma glucose within groups for each intervention

    Comparison of nadir plasma glucose in response to an acute bout of exercise internally in groups a) RYGB and b) control group

    The lowest plasma glucose concentration at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210 OR 240 min after ingestion of meal

  • Impact of glycaemic index on nadir plasma glucose within groups for each intervention

    Comparison of nadir plasma glucose in response to meals with high vs low glycaemic index internally in groups a) RYGB and b) control group

    The lowest plasma glucose concentration at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210 OR 240 min after ingestion of meal

Secondary Outcomes (17)

  • Impact of acute bout of exercise on AUC glucose within groups

    AUC time-concentration-curve for plasma glucose from 0, 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal

  • Impact of acute bout of exercise on delta-fasting-peak glucose within groups

    Difference between fasting plasma glucose and highest plasma glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal

  • Impact of glycaemic index on AUC glucose within groups

    AUC time-concentration-curve for plasma glucose from 0, 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal

  • Impact of glycaemic index on delta-fasting-peak glucose within groups

    Difference between fasting plasma glucose and highest plasma glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal

  • Impact of postprandial exercise and meal glycaemic index on glucagon-like peptide-1 (GLP-1) secretion within the groups determined by differences in AUC

    AUC for time concentration curve of GLP-1 at 0, 10, 20, 30, 35, 60, 90, 120, 150, 180, 240 min after ingestion of meal

  • +12 more secondary outcomes

Other Outcomes (19)

  • Between group differences in delta-fasting-to-peak glucose for each intervention

    difference between fasting glucose and highest glucose concentration at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal

  • Between group differences in delta-peak-nadir glucose for each intervention

    Difference from highest plasma glucose to subsequent lowest plasma glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal

  • Between group differences in nadir plasma glucose for each intervention

    Lowest glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal

  • +16 more other outcomes

Study Arms (2)

10 Roux-en-Y Gastric Bypass patients

EXPERIMENTAL

4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise

Other: Low GI mealtestOther: Low GI mealtest and subsequent exerciseOther: High GI mealtestOther: High GI mealtest and subsequent exercise

10 control subjects

EXPERIMENTAL

4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise

Other: Low GI mealtestOther: Low GI mealtest and subsequent exerciseOther: High GI mealtestOther: High GI mealtest and subsequent exercise

Interventions

Meal with low glycaemic index (GI) is consumed over 20 min

10 Roux-en-Y Gastric Bypass patients10 control subjects

Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min

10 Roux-en-Y Gastric Bypass patients10 control subjects

Meal with high glycaemic index (GI) is consumed over 20 min

10 Roux-en-Y Gastric Bypass patients10 control subjects

Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min

10 Roux-en-Y Gastric Bypass patients10 control subjects

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Achieved \> 50% Excess BMI Loss
  • Weight stability (no fluctuations over ± 5 kg the last 3 months)
  • HBA1c \< 48 mmol/mol before and after surgery without the use of anti-diabetic medication
  • The participant must be able to ingest the meals

You may not qualify if:

  • Low hemoglobin levels (\< 6.5 mM)
  • Pregnancy (determined by human chorionic gonadotropin (hCG) test) or breastfeeding
  • Dysregulated thyroid gland affection
  • The use of medication which affects heart frequency (i.e. Beta-blockers)
  • Complications following RYGB consisting of dysphagia or other problems associated with ingestion of normal foods (i.e. vomit, diarrhea or strong abdominal pain).
  • Control group:
  • Matched with the RYGB patients on gender, age (± 5 years), menopausal state (pre- versus post-menopausal) and BMI (± 3 points).
  • Weight stable ( ± 5 kg during 3 months)
  • HBA1c \< 48 mmol/mol
  • Prior bariatric surgery or prior surgery in the upper gastrointestinal tract.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Endocrinology, Hvidovre Hospital

Hvidovre, DK-2650, Denmark

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Kirstine N Bojsen-Moller, MD, PhD

    Department of Endocrinology, Hvidovre Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Kirstine Nyvold Bojsen-Moeller

Study Record Dates

First Submitted

February 6, 2018

First Posted

March 27, 2018

Study Start

March 1, 2018

Primary Completion

March 1, 2020

Study Completion

March 1, 2020

Last Updated

June 15, 2023

Record last verified: 2023-06

Locations